

**Retina Update Featuring the 1st Annual Joseph I. Maguire, MD Memorial Lecture**

**Saturday, April 13, 2024**

*Wills Eye Auditorium*

**[Conference Description:](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)**

[Click Here to Register for the Livestream!](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[With the emergence of new technologies, treatments, and clinical trial results, ophthalmologists need to understand how to incorporate these advances into clinical care. We will discuss latest advances in the management of inherited and acquired ophthalmic diseases and evidence for emerging therapies and screening modalities. Both didactic and case-based educational formats will be utilized to illustrate current trends in the management of complex and routine ophthalmic patients, taking into account diagnostics as well as nonsurgical and surgical treatment.](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Thank you to our exhibitors!](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Alcon](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Allergan](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Apellis](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Astellas](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Genentech](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Regeneron](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

[Sandoz](https://willseye.cloud-cme.com/assets/willseye/pdf/Exhibitors/20240413%20Retina%20Exhibitor%20linksheet.pdf%22%20Thank%20you%20to%20our%20exhibitors%21AlconAllerganApellisAstellasGenentechRegeneronSandoz%22%20%22)

**Accreditation Statement:**

The Wills Eye Hospital is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

**Credit Statement Designation:**

Wills Eye Hospital designates this Live Activity for a maximum of 4.00 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

**Disclosure Statement:**

It is the policy of Wills Eye Hospital that the information presented at Wills Eye Hospital's CME activities will be commercially unbiased and based on scientific and clinical evidence. To help participants make judgments about the presence of commercial bias, Wills Eye Hospital provides information that planners and speakers have disclosed about financial relationships they have with commercial entities that produce, market, re-sell, or distribute health care goods or services consumed by, or used on, patients. All relevant financial relationships have been mitigated.

|  |  |  |
| --- | --- | --- |
| **Name of individual** | **Individual's role in activity** | **Nature of Relationship(s) / Name of Ineligible Company(s)** |
| Ralph C. Eagle Jr., MD | Other Planning Committee Member | Nothing to disclose - 03/06/2024 |
| Mitchell S. Fineman, MD | Faculty | Nothing to disclose - 01/23/2024 |
| James F. Vander, MD | Faculty | Nothing to disclose - 12/08/2023 |
| Samir N Patel, MD | Faculty | Nothing to disclose - 02/27/2024 |
| Meera Sivalingam, MD | Faculty | Nothing to disclose - 11/14/2023 |
| Allen Chiang, MD | Faculty | Grant or research support-Genentech|Consulting Fee-Novartis (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Apellis Pharmaceuticals|Consulting Fee-Apellis Pharmaceuticals (Relationship has ended) - 03/18/2024 |
| Jason Hsu, MD | Faculty | Consulting Fee-Iveric Bio|Consulting Fee-Gyroscope Therapeutics|Grant or research support-Genentech|Grant or research support-Iveric Bio|Grant or research support-Aldeyra Therapeutics (Relationship has ended) - 12/01/2023 |
| Carl D. Regillo, MD | Faculty | Consulting Fee-Allergan|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-EyePoint Pharmaceuticals|Consulting Fee-Genentech|Consulting Fee-Novartis|Consulting Fee-Ocugen|Consulting Fee-REGENXBIO, Inc.|Consulting Fee-Regeneron|Consulting Fee-Astellas Pharma|Consulting Fee-Ocular Therapeutix|Consulting Fee-Zeiss|Consulting Fee-Sanofi (Relationship has ended)|Consulting Fee-Aderum Biotechnologies, Inc.|Consulting Fee-Alcon|Consulting Fee-Bausch + Lomb|Consulting Fee-Boehringer Ingelheim - 12/11/2023 |
| Ajay E. Kuriyan, MD | Faculty | Stocks or stock options, excluding diversified mutual funds-Recens medical|Grant or research support-4DMT|Speakers Bureau-Genentech|Speakers Bureau-Astellas Pharma|Consulting Fee-Alimera Sciences (Relationship has ended)|Grant or research support-Alcon|Grant or research support-Aderum Biotechnologies, Inc.|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Bausch + Lomb (Relationship has ended)|Consulting Fee-Spark Therapeutics (Relationship has ended)|Consulting Fee-EyePoint Pharmaceuticals (Relationship has ended)|Consulting Fee-Genentech (Relationship has ended)|Grant or research support-Genentech (Relationship has ended)|Consulting Fee-Optos, Inc. (Relationship has ended)|Grant or research support-Annexon - 02/15/2024 |
| Omesh P. Gupta, MD, MBA | Faculty, Planner | Nothing to disclose - 12/06/2023 |
| Yoshihiro Yonekawa, MD | Faculty | Paid consultant-Alcon|Advisor-Pykus|Paid consultant-EyePoint Pharmaceuticals (Relationship has ended) - 03/18/2024 |
| Jose Pulido, MD, MS, MPH, MBA | Faculty | Nothing to disclose - 12/09/2023 |
| Sunir J. Garg, MD | Faculty | Consulting Fee-Bausch + Lomb|Consulting Fee-Johnson & Johnson|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-Boehringer Ingelheim|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Regeneron|Consulting Fee-Coherus Biosciences|Grant or research support-Allergan|Grant or research support-Boehringer Ingelheim|Grant or research support-Genentech|Grant or research support-Regeneron|Grant or research support-Apellis Pharmaceuticals|Grant or research support-NGM Bio|Grant or research support-Kodiak Sciences|Grant or research support-Alcon - 04/09/2024 |
| Murtaza Adam, MD | Faculty | Speakers Bureau-Apellis Pharmaceuticals|Consulting Fee-Regeneron|Speakers Bureau-Regeneron|Speakers Bureau-Genentech|Consulting Fee-Genentech|Consulting Fee-Roche|Speakers Bureau-Astellas Pharma|Consulting Fee-Dutch Ophthalmic USA (Relationship has ended)|Consulting Fee-Allergan (Relationship has ended)|Consulting Fee-NorthGauge Healthcare - 02/28/2024 |
| Joshua H Uhr, MD | Faculty | Public Corp Stock-Apellis Pharmaceuticals|Consulting Fee-Regeneron - 04/09/2024 |
| James P. Dunn, MD | Faculty | Nothing to disclose - 03/12/2024 |
| Allen Ho, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Alcon|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Novartis|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech|Independent Contractor (included contracted research)-Kodiak Sciences|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Notal Vision|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Regeneron|Membership on Advisory Committees or Review Panels, Board Membership, etc.-REGENXBIO, Inc. - 04/27/2023 |
| Richard S. Kaiser, MD | Faculty | Nothing to disclose - 12/04/2023 |
| Anton Orlin, MD | Faculty | Membership on Advisory Committees or Review Panels, Board Membership, etc.-Allergan (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Zeiss (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Genentech (Relationship has ended)|Membership on Advisory Committees or Review Panels, Board Membership, etc.-Apellis Pharmaceuticals (Relationship has ended) - 04/24/2023 |
| Michael N Cohen, MD | Faculty, Planner | Nothing to disclose - 11/18/2023 |
| Michael Klufas, MD | Faculty | Consulting Fee-REGENXBIO, Inc.|Honoraria-Genentech|Honoraria-Regeneron|Honoraria-Coherus|Honoraria-Biogen|Consulting Fee-Abbvie|Grant or research support-Bausch + Lomb|Consulting Fee-Dutch Ophthalmic USA|Consulting Fee-Alimera Sciences - 11/14/2023 |
| Ehsan Rahimy, MD | Faculty | Consulting Fee-Regeneron|Consulting Fee-Genentech|Consulting Fee-Apellis Pharmaceuticals|Consulting Fee-Allergan|Consulting Fee-Astellas Pharma|Consulting Fee-Zeiss|Speakers Bureau-Regeneron|Speakers Bureau-Genentech|Speakers Bureau-Apellis Pharmaceuticals|Speakers Bureau-Allergan - 02/27/2024 |
| Steve Houston, MD | Faculty | Consulting Fee-Alcon - 03/05/2024 |
| David Reed, MD | Faculty | Nothing to disclose - 03/25/2024 |

